{"entity":{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","aka":[],"tldr":"Lorigerlimab is an experimental bispecific antibody from MacroGenics in phase 2 trials for ovarian cancer, vulvar cancer and cervical cancer, aimed at PD-1 and CTLA-4.","summary":"Lorigerlimab (MGD019) is a bispecific antibody developed by MacroGenics. Its targets are PD-1 and CTLA-4 (the sponsor names PD-1 x CTLA-4). The sponsor states: A DART (Dual Affinity Re-Targeting) bispecific protein that simultaneously engages the PD-1 and CTLA-4 checkpoint pathways to enhance anti-tumour immune responses. ClinicalTrials.gov describes the intervention as: Bispecific DART protein binding PD-1 and CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, vulvar cancer, cervical cancer and endometrial cancer. The largest, NCT06730347, plans to enrol 80 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Lorigerlimab","url":"https://clinicaltrials.gov/search?intr=MGD019"},{"label":"Sponsor pipeline page","url":"https://macrogenics.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","vulvar","cervical","endometrial"],"sections":[],"technologies":[],"targets":["pd1","ctla4"],"drugs":[],"companies":["macrogenics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06730347"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"MGD019","modality":"bispecific antibody","mechanism":"A DART (Dual Affinity Re-Targeting) bispecific protein that simultaneously engages the PD-1 and CTLA-4 checkpoint pathways to enhance anti-tumour immune responses.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lorigerlimab/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/"}],"trial":[{"id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/"},{"id":"nct07071961","kind":"trial","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","route":"/trials/nct07071961/"}]}}